• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部进展期直肠癌新辅助放化疗联合诱导或巩固化疗的汇总分析

A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer.

机构信息

Department of Radiation Oncology, Oncology Center, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510282, China.

出版信息

J Gastrointest Cancer. 2023 Sep;54(3):693-702. doi: 10.1007/s12029-022-00864-6. Epub 2022 Oct 15.

DOI:10.1007/s12029-022-00864-6
PMID:36243897
Abstract

OBJECTIVE

Total neoadjuvant therapy (TNT) combining chemoradiotherapy (CRT) with chemotherapy (CT) was a novel pre-surgical approach to cancer treatment. This meta-analysis aimed to compare the clinical outcomes between neoadjuvant CRT (nCRT) with induction CT and nCRT with consolidated CT in locally advanced rectal cancer (LARC) patients.

METHOD

In July 2022, a literature search was conducted using the following public databases: PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science, retrieved all relevant articles comparing nCRT-combining induction CT with nCRT-combining-consolidated CT treatments for LARC patients.

RESULTS

Four eligible studies were identified, including a total of 995 LARC patients: 473 in the nCRT with consolidated CT group and 522 in the nCRT with induction CT group. The organ preservation (OP) rate of the nCRT with consolidated CT group was higher than that of the nCRT with induction CT group (RR [relative risk]: 1.53; 95% CI (confidence interval): 1.09-2.14). The pathological complete response (PCR, RR: 1.22; 95% CI 0.37-2.17), the 3-year disease-free survival (DFS, RR 1.02; 95% CI 0.71-1.46), the local recurrence (LR, RR 0.98; 95% CI 0.52-1.85), rates of R0 resection (RR 0.74; 95% CI 0.55-1.10), compliance (RR 0.52; 95% CI 0.12-2.26), and grade 3--4 toxicities (RR 0.78; 95% CI 0.57-1.06) were all similar between the two groups.

CONCLUSION

In this meta-analysis of TNT regimens for rectal cancer, consolidative CT following nCRT was associated with similar PCR, 3-year DFS, LR, R0 resection, compliance, and grade 3-4 toxicities compared to induction CT prior to nCRT but a higher rate of organ preservation.

摘要

目的

新辅助放化疗(CRT)联合化疗(CT)的全新辅助治疗(TNT)是一种癌症治疗的新术前方法。本荟萃分析旨在比较局部晚期直肠癌(LARC)患者中新辅助 CRT(nCRT)联合诱导 CT 与 nCRT 联合巩固 CT 的临床疗效。

方法

2022 年 7 月,检索了以下公共数据库中的文献:PubMed、MEDLINE、Embase、Cochrane 图书馆和 Web of Science,以比较 nCRT 联合巩固 CT 与 nCRT 联合诱导 CT 治疗 LARC 患者的相关文献。

结果

共纳入 4 项符合条件的研究,共纳入 995 例 LARC 患者:nCRT 联合巩固 CT 组 473 例,nCRT 联合诱导 CT 组 522 例。nCRT 联合巩固 CT 组的器官保留(OP)率高于 nCRT 联合诱导 CT 组(RR [相对风险]:1.53;95%CI [置信区间]:1.09-2.14)。nCRT 联合巩固 CT 组的病理完全缓解(PCR,RR:1.22;95%CI 0.37-2.17)、3 年无病生存率(DFS,RR 1.02;95%CI 0.71-1.46)、局部复发率(LR,RR 0.98;95%CI 0.52-1.85)、R0 切除率(RR 0.74;95%CI 0.55-1.10)、依从性(RR 0.52;95%CI 0.12-2.26)和 3-4 级毒性发生率(RR 0.78;95%CI 0.57-1.06)均相似。

结论

在这项直肠癌 TNT 方案的荟萃分析中,与 nCRT 前诱导 CT 相比,nCRT 后巩固 CT 与更高的器官保留率相关,但与 PCR、3 年 DFS、LR、R0 切除、依从性和 3-4 级毒性相似。

相似文献

1
A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer.局部进展期直肠癌新辅助放化疗联合诱导或巩固化疗的汇总分析
J Gastrointest Cancer. 2023 Sep;54(3):693-702. doi: 10.1007/s12029-022-00864-6. Epub 2022 Oct 15.
2
[Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].全新辅助治疗与新辅助放化疗治疗局部晚期直肠癌的疗效和安全性:一项荟萃分析
Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Jun 25;25(6):531-538. doi: 10.3760/cma.j.cn441530-20210806-00311.
3
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术:初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
4
Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis of 15 trials.局部晚期直肠癌的新辅助放化疗与标准治疗的比较:15 项试验的系统评价和荟萃分析。
PLoS One. 2022 Nov 4;17(11):e0276599. doi: 10.1371/journal.pone.0276599. eCollection 2022.
5
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery for patients with locally advanced rectal cancer: a systematic review and meta-analysis.局部晚期直肠癌患者行诱导化疗后新辅助放化疗和手术治疗:系统评价和荟萃分析。
Int J Colorectal Dis. 2020 Aug;35(8):1355-1369. doi: 10.1007/s00384-020-03621-y. Epub 2020 Jun 1.
6
[Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].局部晚期直肠癌患者新辅助治疗与全新辅助治疗的短期疗效及围手术期安全性比较
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):274-280. doi: 10.3760/cma.j.cn.441530-20190819-00312.
7
Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis.局部晚期直肠癌的全新辅助治疗(TNT)与标准新辅助放化疗:一项系统评价和荟萃分析
Oncologist. 2021 Sep;26(9):e1555-e1566. doi: 10.1002/onco.13824. Epub 2021 Jun 7.
8
Compare clinical efficacy and safety of neoadjuvant therapy and neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Meta-analysis.比较新辅助治疗与新辅助放化疗对局部晚期直肠癌的临床疗效和安全性:Meta分析。
World J Gastrointest Surg. 2024 Jun 27;16(6):1845-1856. doi: 10.4240/wjgs.v16.i6.1845.
9
Is Total Neoadjuvant Treatment Beneficial for Locally Advanced Rectal Cancer? A Meta-Analysis of Randomized Controlled Trials.全新辅助治疗对局部进展期直肠癌有益吗?一项随机对照试验的荟萃分析。
Oncology. 2024;102(5):399-413. doi: 10.1159/000534815. Epub 2023 Nov 3.
10
Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A Systematic Review and Network Meta-Analysis.局部晚期直肠癌新辅助放化疗时代的治疗选择:系统评价和网络荟萃分析。
JAMA Netw Open. 2024 Jun 3;7(6):e2414702. doi: 10.1001/jamanetworkopen.2024.14702.

引用本文的文献

1
Predictive value of a nomogram model for treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.列线图模型对局部晚期直肠癌新辅助放化疗治疗反应的预测价值
World J Gastrointest Oncol. 2025 Jul 15;17(7):105403. doi: 10.4251/wjgo.v17.i7.105403.
2
Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?选择局部晚期直肠癌的短程放疗方案:我们能否预测谁真正能从中获益?
Cancers (Basel). 2023 Apr 30;15(9):2567. doi: 10.3390/cancers15092567.

本文引用的文献

1
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.局部晚期直肠癌患者的 FOLFIRINOX 新辅助化疗和术前放化疗(UNICANCER-PRODIGE 23):一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 May;22(5):702-715. doi: 10.1016/S1470-2045(21)00079-6. Epub 2021 Apr 13.
2
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.短程放疗联合化疗后行全直肠系膜切除术(TME)与术前放化疗、TME 及辅助化疗在局部进展期直肠癌(RAPIDO)中的应用:一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7.
3
Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial.优化直肠癌患者化疗的治疗顺序:KIR 随机二期试验。
Radiother Oncol. 2021 Feb;155:237-245. doi: 10.1016/j.radonc.2020.11.008. Epub 2020 Nov 19.
4
Colorectal cancer statistics, 2020.2020 年结直肠癌统计数据。
CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.
5
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial.直肠癌术前治疗中的诱导化疗、放化疗和巩固化疗——OIGIT-01 试验 II 期的长期结果。
Radiol Oncol. 2018 Sep 11;52(3):267-274. doi: 10.2478/raon-2018-0028.
6
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.放化疗后联合 mFOLFOX6 化疗巩固治疗可改善局部晚期直肠癌患者的生存:一项多中心 II 期试验的最终结果。
Dis Colon Rectum. 2018 Oct;61(10):1146-1155. doi: 10.1097/DCR.0000000000001207.
7
A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.一项比较局部进展期直肠癌术前放化疗后巩固化疗与单纯放化疗的随机 2 期临床试验:KCSG CO 14-03。
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899. doi: 10.1016/j.ijrobp.2018.04.013. Epub 2018 Apr 12.
8
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.局部晚期直肠癌的全新辅助治疗的采用。
JAMA Oncol. 2018 Jun 14;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071.
9
Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer.局部复发性直肠癌基于诱导化疗的治疗队列研究的初步结果。
Br J Surg. 2018 Mar;105(4):447-452. doi: 10.1002/bjs.10694. Epub 2017 Nov 23.
10
Total neoadjuvant therapy for rectal cancer: An emerging option.直肠癌的新辅助治疗:一种新兴的选择。
Cancer. 2017 May 1;123(9):1497-1506. doi: 10.1002/cncr.30600. Epub 2017 Mar 10.